The Trump administration is blocking imports from BGI Group, BGI Genomics and MGI Tech starting Thursday, with Customs and Border Protection enforcing the restriction. DHS cites corporate and government reporting and alleges links to forced labor and genetic testing in Xinjiang; BGI Group denies engaging in forced labor, and the Chinese government rejects broader claims about the region. The action uses the Uyghur Forced Labor Prevention Act, which was signed in 2021. The administration expanded the law’s blacklist in August to 187 entities. The excerpt names no new state or local enforcement duties, fees, forms or quantified consumer costs; implementation details beyond the federal import bar are not provided.
TLDR: Federal customs officials will bar shipments from three Chinese biotech companies starting Thursday under the Uyghur Forced Labor Prevention Act. DHS alleges links to forced labor in Xinjiang, while BGI Group denies the allegations; the excerpt does not specify new state or local duties or added fees.
The Trump administration is blocking imports from three Chinese biotech companies under a federal law aimed at preventing goods linked to forced labor from entering the United States. U.S. Customs and Border Protection will bar shipments from BGI Group, BGI Genomics and MGI Tech starting Thursday. The restriction is a direct federal action, with an immediate effect at the border.
The stated rationale is straightforward: the Department of Homeland Security says credible corporate and government reporting links the companies to genetic testing in Xinjiang and indicates they may source materials there or work with the regional government in ways connected to forced labor. DHS says genetic data collection and analysis can support surveillance and repression of ethnic minorities, including Uyghurs. That is the basis for applying the Uyghur Forced Labor Prevention Act to these firms.
The law was signed at the end of 2021 by then-President Joe Biden, following allegations of human rights abuses against Uyghurs and other Muslim minorities in Xinjiang. The Trump administration’s action puts the law to work against named companies. It also places a clear responsibility on federal border officials: shipments covered by the restriction are to be stopped rather than allowed through under ordinary trade rules.
The allegations remain disputed. BGI Group said Wednesday that it has not engaged in forced labor and opposes all forms of it. The Chinese government has rejected the broader claims about Xinjiang, calling them lies and describing its policies there as efforts to fight terror and ensure stability. The administration’s import action rests on DHS’s cited information, while the company and Chinese government deny the allegations.
BGI Group is known for genetic sequencing technologies and holds controlling stakes in BGI Genomics and MGI Tech, according to DHS. U.S. lawmakers and policymakers have also raised concerns about the company’s alleged ties to the Chinese government and its access to large volumes of genetic data. They worry that those issues could affect American national security and commercial interests. BGI has stressed that it is privately owned, does not serve U.S. patients and has no access to Americans’ genetic data.
The dispute sits within a wider contest over technology and trade. Biotechnology has become another area of U.S.-China economic competition. Last week, the Treasury Department proposed new limits on U.S. investment in biotechnology, artificial intelligence and supercomputing in countries such as China. Those proposed limits are separate from the import restriction, which begins Thursday and applies to goods from the three named firms.
Congress did not pass legislation that would have barred BGI from doing business with federally funded medical providers. At the end of last year, however, lawmakers approved a similar provision that did not identify companies by name and called for a list of biotechnology companies of concern. The Pentagon has separately labeled BGI Group, BGI Genomics and MGI Tech Chinese military companies, a designation the excerpt says carries reputational damage.
The current restriction is part of a larger enforcement effort under the Uyghur Forced Labor Prevention Act. In August, the Trump administration added 43 Chinese companies to the law’s blacklist, bringing the total to 187 entities. Homeland Security Secretary Markwayne Mullin has said the administration intends to protect American workers from being undercut or cheated by foreign companies using forced labor. The new listing extends that approach into biotechnology supply chains.
The practical impact is specific at the border but less clear elsewhere. Beginning Thursday, Customs and Border Protection will bar goods from BGI Group, BGI Genomics and MGI Tech. Importers and businesses handling those goods will face the resulting restriction on shipments. The excerpt gives no fee, new form, separate compliance deadline, or estimate of effects on consumers. It also does not identify state or local enforcement duties, or quantify any costs or delays for businesses or buyers; those details are not stated as part of the plan.
The restriction narrows the freedom of the named firms to ship goods into the U.S. and limits the choices available to businesses that might otherwise import them. It also places more weight on federal enforcement and on the administration’s assessment of information about supply chains. Those are real changes to trade and commercial discretion. The administration has chosen a firm rule over leaving the issue to voluntary decisions by companies and buyers.
For state and local governments, the available account identifies no new role beyond the federal border action. The next defined step is implementation by Customs and Border Protection beginning Thursday. The law’s blacklist has expanded, and further oversight or compliance procedures are not detailed in the excerpt. The import bar and the agency’s enforcement of it are the necessary steps now described; the record provided does not establish additional assurances or oversight plans.
Dylan Brooks serves as the Senior Correspondent for Statehouses and Local Governance at Just Right News, where he brings a principled, constitutionalist lens to the often-overlooked machinery of state-level politics. As the lead voice behind the acclaimed feature series “Fifty Laboratories of Power,” Dylan has dedicated his career to the idea that the most impactful governance happens closest to home. His reporting consistently champions the Tenth Amendment, exploring how individual states can serve as testing grounds for innovative, conservative policy solutions that prioritize personal liberty and fiscal responsibility.
A native of Des Moines, Iowa, Dylan’s journalistic philosophy was forged in the heart of the American Midwest. Growing up in a community where local school board meetings and town halls were the bedrock of civic life, he developed a deep appreciation for the “retail politics” of the heartland. This upbringing instilled in him a fundamental belief that the American experiment is best preserved when power is decentralized. He carries the values of his Iowa roots into every assignment, maintaining a healthy skepticism of federal overreach and a steadfast commitment to the concerns of everyday citizens over the interests of the administrative state.
Now based in Madison, Wisconsin, Dylan operates from one of the nation’s most pivotal political battlegrounds. His location in a state capital known for its rigorous policy debates allows him to provide Just Right News readers with a front-row seat to the legislative process. From Madison, he tracks the ripple effects of statehouse decisions on local municipalities, ensuring that the connection between high-level policy and community impact is never lost. His work often highlights the success of conservative governors and legislatures in fostering economic growth, protecting parental rights, and securing the integrity of local institutions.
As an African American man in the conservative media landscape, Dylan offers a vital perspective on how limited government and free-market principles empower individuals and families. He frequently reports on how deregulation and school choice initiatives provide new avenues for success in underserved communities, challenging the monolithic narratives often presented by legacy media outlets. Dylan’s work is characterized by a commitment to the facts and a refusal to shy away from the complex realities of modern governance.
Throughout his tenure at Just Right News, Dylan has become a trusted authority for readers who value a rigorous, principled approach to the news. Whether he is dissecting a complex state budget or profiling a local grassroots movement, his goal remains the same: to provide the American public with the information they need to hold their local leaders accountable. By focusing on the “Fifty Laboratories of Power,” Dylan Brooks ensures that the vital work being done in statehouses across the country receives the national attention it deserves, always through a lens that respects the traditions and sovereignty of the American people.